Welcome to our dedicated page for BiomX news (Ticker: PHGE), a resource for investors and traders seeking the latest updates and insights on BiomX stock.
BiomX Inc. (NYSE American: PHGE) is a pioneering clinical-stage microbiome and drug discovery company based in Israel. The company specializes in the development of natural and engineered phage therapies designed to target and destroy harmful bacteria associated with chronic diseases such as inflammatory bowel disease (IBD), colorectal cancer, primary sclerosing cholangitis, and chronic pulmonary infections in cystic fibrosis (CF) patients.
Utilizing advanced computational and synthetic biology research from globally renowned institutions, including the Weizmann Institute of Science and the Massachusetts Institute of Technology (MIT), BiomX's platforms discover and validate proprietary bacterial targets. Their flagship product candidate, BX004, aims to treat chronic pulmonary infections caused by Pseudomonas aeruginosa in CF patients. This program has shown promising clinical results, achieving positive outcomes in both safety and efficacy in Part 2 of a Phase 1b/2a trial, with results expected to be published in November 2023. BX004 has been granted Fast Track designation by the FDA.
In addition to its CF program, BiomX has expanded its pipeline through a recent merger with Adaptive Phage Therapeutics (APT), adding BX211, a personalized phage treatment for diabetic foot osteomyelitis (DFO) caused by Staphylococcus aureus. This merger has bolstered BiomX's capabilities and financial resources, enabling the company to advance its clinical pipeline effectively.
BiomX enjoys strong backing from notable investors such as OrbiMed Israel Incubator LP, Johnson & Johnson Development Corporation, Takeda Ventures, Seventure Partners, Mirae Asset Global Investments, and SBI.
For more details on BiomX's ongoing projects and latest developments, visit www.biomx.com.
BiomX (PHGE) updates on its Phase 1b/2a trial for BX004, targeting lung infections in cystic fibrosis (CF), with results expected by Q3 2022. The company entered a collaboration with Boehringer Ingelheim to discover microbiome markers for inflammatory bowel disease. BiomX published significant research articles, including one in Cell, and has extended its cash runway through mid-2024 with a current cash position of $46.7 million. Despite a net loss of $7.5 million in Q2 2022, the company is focused on key milestones to enhance shareholder value.
BiomX Inc. (NYSE American: PHGE) announced a conference call on August 10, 2022, at 8:00 a.m. EDT to discuss its second-quarter financial results and business updates. The company specializes in developing natural and engineered phage therapies targeting pathogenic bacteria for chronic disease treatment. Investors can participate by calling a designated number or accessing the webcast through the company's website.
BiomX Inc. (PHGE) announced the publication of a significant study confirming the efficacy of its phage therapy candidate BX003 targeting Klebsiella pneumoniae in inflammatory bowel disease (IBD). Conducted with leading academic institutions, the research demonstrated safety and tolerability in a Phase 1a trial, as well as effective suppression of pathogenic bacteria in colitis-prone mice. The findings enhance the scientific basis for BX003’s potential in treating IBD, emphasizing collaboration in advancing treatment for challenging diseases.
BiomX Inc. (NYSE American: PHGE) announced its decision to voluntarily delist from the Tel Aviv Stock Exchange (TASE), effective October 6, 2022. This move is based on a review of trading volumes and the costs associated with maintaining multiple exchange listings. BiomX believes that consolidating its listing to the NYSE American is in the best interest of shareholders. Following the delisting, all shares on the TASE will transition to continue trading on the NYSE American.
BiomX has announced a collaboration with Boehringer Ingelheim to identify biomarkers for inflammatory bowel disease (IBD) using its XMarker discovery platform. This collaboration follows their first in September 2020, demonstrating ongoing partnership efforts in IBD research. BiomX aims to leverage its technology to help delineate patient segments based on their microbiome, potentially enhancing treatment specificity. The agreement includes research payments and an option for Boehringer Ingelheim to obtain exclusive rights to any discovered biomarkers, while BiomX retains rights for companion diagnostics.
BiomX (AMEX: PHGE) announced the dosing of its first two patients in a Phase 1b/2a study evaluating BX004 for treating chronic respiratory infections in cystic fibrosis patients. This clinical milestone is aimed at assessing BX004's safety and clinical activity against antibiotic-resistant P. aeruginosa. Results from Part 1 are expected in Q3 2022, followed by Part 2, which involves a larger cohort. The company received a $5 million award from the Cystic Fibrosis Foundation to support its development efforts.
BiomX (AMEX: PHGE) announces a corporate restructuring plan to enhance capital resources, cutting headcount by 50%. The cash runway is extended to at least mid-2024, with $55.7 million in cash and a $15 million debt facility reported as of March 31, 2022. The Cystic Fibrosis (CF) program is progressing, with initial results from the Phase 1b/2a study of BX004 expected in Q3 2022. However, the Atopic Dermatitis program will face delays due to the restructuring.
BiomX (NYSE American: PHGE) announced the publication of a scientific paper on the Exodus algorithm, enhancing the identification of genetically-related microorganisms. The Exodus algorithm improves the quantification of pooled genomes, achieving median error rates between 0% and 0.21%. Notably, the algorithm recorded no false negatives, indicating high accuracy even with low-abundance genomes. This advancement is expected to optimize the detection of virus variants and aid in the analysis of various genomic projects.
BiomX (PHGE) has made significant strides in its pipeline, particularly in treating cystic fibrosis (BX004) and atopic dermatitis (BX005). The Phase 1b/2a trial for BX004 is set to begin, with initial results expected by Q3 2022. The IND for BX005 has been approved, with data readouts anticipated in Q4 2022. Financially, the company reported a cash balance of $55.7 million as of March 31, 2022, down from $63.1 million, primarily due to operating expenses. Despite a net loss of $8.2 million, the cash runway is projected to last through 2023.
BiomX Inc. (NYSE American: PHGE) will host a virtual key opinion leader webinar on May 12, 2022, at 11:00 AM EDT to discuss BX004, a phage therapy aimed at treating Pseudomonas Aeruginosa infections in cystic fibrosis patients. The FDA cleared BX004 for a Phase 1b/2a trial in September 2021, with initial data expected in Q3 2022. Key Opinion Leaders Dr. Dave Nichols and Dr. Saima Aslam will present, followed by BiomX CEO Jonathan Solomon. Registration is available on BiomX's website.
FAQ
What is the current stock price of BiomX (PHGE)?
What is the market cap of BiomX (PHGE)?
What does BiomX Inc. specialize in?
What is BX004?
Who are BiomX's research partners?
What recent merger did BiomX complete?
Who are some of BiomX's investors?
What are some of BiomX's current projects?
Where is BiomX Inc. based?
What technological platforms does BiomX use?
When can we expect results for BX004 Phase 1b/2a trial?
How can I get more information about BiomX?
